Defining Frailty in Multiple Myeloma for Optimal Treatment
Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.
Read More
Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.
Read More
Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma
Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.
Read More
Key Takeaways From the ASH 2021 Meeting on Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
January 25th 2022Closing out her discussion on the management of newly diagnosed and relapsed/refractory multiple myeloma, Amrita Y. Krishnan, MD, shares key takeaways from the ASH 2021 Annual Meeting.
Read More
Dr. Krishnan on Key Aspects of the ELOQUENT Trials in Relapsed/Refractory Multiple Myeloma
September 11th 2019Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and a professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses key aspects of the phase III ELOQUENT-2 and -3 trials in relapsed/refractory multiple myeloma.
Read More